Compare BridgeBio Pharma Inc (BBIO) vs Constellation Energy Corporation (CEG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Constellation Energy Corporation — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Constellation Energy Corporation trades at $279.2 (market cap $95.82B). The key difference: Constellation Energy Corporation is far larger — about 5.8× BridgeBio Pharma Inc's market cap, and Constellation Energy Corporation pays a 0.63% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | CEG | |
|---|---|---|
Market Cap | $16.61B | $95.82B |
Sector | Health | Energy |
52-Week High | $90.17 | $403.95 |
52-Week Low | $47.29 | $236.50 |
Enterprise Value | $18.16B | $119.82B |
Dividend Yield | — | 0.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Constellation Energy (CEG) trades at $269.89, up 3.37% with a bullish technical outlook. The stock shows strong fundamentals with Q2 2026 EPS beating estimates at $2.55 versus $2.29 expected, and the company raised its 2026 guidance. Recent news highlights new power deals, including a Walmart PPA, and the acquisition of Calpine, positioning CEG to benefit from AI-driven electricity demand.
The outlook is positive with a consensus price target of $333.14, implying significant upside. Key opportunities include nuclear energy's role in the AI power boom and strong cash flow generation. Risks involve execution of growth initiatives and potential regulatory changes affecting the utilities sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Constellation Energy Corporation
Constellation is the largest producer of carbon-free energy in the U.S. and a leading nuclear power plant operator. It provides sustainable electricity to millions of residential, public, and industrial customers.
Read more on CEG →
